|
|
|
| Levofloxacin preventive treatment for close contacts of drug-resistant tuberculosis patients: a review |
| ZU Zhipeng1, CHEN Ruiqi1, CHEN Haiting2, WANG Xiaomeng1
|
1. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China;
2. School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China |
|
|
|
|
Abstract Close contacts of rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB) patients are at high risk of latent tuberculosis infection (LTBI) and active TB. Preventive treatment for this group is a key strategy to block the spread of drug-resistant TB. Levofloxacin is a core fluoroquinolone anti-TB drug. It has good antibacterial activity, pharmacokinetic properties, and safety. It can significantly reduce the risk of progression to active TB in close contacts of RR/MDR-TB patients. Therefore, it is an important candidate drug for preventive treatment. Based on evidence from the TB-CHAMP and V-QUIN trials, the World Health Organization (WHO) recommended a 6-month levofloxacin regimen in 2024 for preventive treatment in close contacts of RR/MDR-TB patients. This paper searched for literature from 2000 to 2026. It reviews the clinical efficacy, dose optimization in adults and children, and safety of levofloxacin in preventive treatment for close contacts of drug-resistant TB patients. The aim is to provide evidence for optimizing drug-resistant TB control.
|
|
Received: 23 March 2026
Revised: 08 May 2026
Published: 27 May 2026
|
|
|
|
|
|
[1] World Health Organization.Global tuberculosis report 2024[R].Geneva:WHO,2024.
[2] World Health Organization.WHO consolidated guidelines on tuberculosis:module 4:treatment-drug-resistant tuberculosis treatment[EB/OL].[2026-05-08].https://www.who.int/publications/i/item/9789240107243.
[3] YANG C G,LUO T,SHEN X,et al.Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai,China:a retrospective observational study using whole-genome sequencing and epidemiological investigation[J].Lancet Infect Dis,2017,17(3):275-284.
[4] KHERABI Y,TUNESI S,KAY A,et al.Preventive therapy for contacts of drug-resistant tuberculosis[J/OL].Pathogens,2022,11(10)[2026-05-08].https://doi.org/10.3390/pathogens11101189.
[5] ORGANIZAT W H.WHO consolidated guidelines on tuberculosis.Module 1:Prevention.Tuberculosis preventive treatment[J].Tuberc Lung Dis HIV Infect,2021(2):86-92.
[6] World Health Organization.WHO consolidated guidelines on tuberculosis:module 1:prevention-infection prevention and control[EB/OL].[2026-05-08].https://www.who.int/publications/i/item/9789240096196.
[7] HESSELING A C,PURCHASE S E,MARTINSON N A,et al.Levofloxacin preventive treatment in children exposed to MDR tuberculosis[J].N Engl J Med,2024,391(24):2315-2326.
[8] FOX G J,NHUNG N V,CAM BINH N,et al.Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam[J].N Engl J Med,2024,391(24):2304-2314.
[9] ORGANIZAT W H.WHO consolidated guidelines on tuberculosis.Module 1:Prevention.Tuberculosis preventive treatment[J].Tuberc Lung Dis HIV Infect,2021(2):86-92.
[10] HOUBEN R M,DODD P J.The global burden of latent tuberculosis infection:a re-estimation using mathematical modelling[J/OL].PLoS Med,2016,13(10)[2026-05-08].https://doi.org/10.1371/journal.pmed.1002152.
[11] KNIGHT G M,MCQUAID C F,DODD P J,et al.Global burden of latent multidrug-resistant tuberculosis:trends and estimates based on mathematical modelling[J].Lancet Infect Dis,2019,19(8):903-912.
[12] KENDALL E A,FOFANA M O,DOWDY D W.Burden of transmitted multidrug resistance in epidemics of tuberculosis:a transmission modelling analysis[J].Lancet Respir Med,2015,3(12):963-972.
[13] CHIANG S S,BROOKS M B,JENKINS H E,et al.Concordance of drug-resistance profiles between persons with drug-resistant tuberculosis and their household contacts:a systematic review and meta-analysis[J].Clin Infect Dis,2021,73(2):250-263.
[14] ZHOU G Z,LUO S Q,HE J,et al.Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis:a systematic review and meta-analysis[J].Clin Microbiol Infect,2024,30(2):189-196.
[15] SHAH N S,YUEN C M,HEO M,et al.Yield of contact investigations in households of patients with drug-resistant tuberculosis:systematic review and meta-analysis[J].Clin Infect Dis,2014,58(3):381-391.
[16] KIM S,WU X Y,HUGHES M D,et al.High prevalence of tuberculosis infection and disease in child household contacts of adults with rifampin-resistant tuberculosis[J/OL].Pediatr Infect Dis J,2022,41(5)[2026-05-08].https://doi.org/10.1097/INF.0000000000003505.
[17] MARKS S M,MASE S R,MORRIS S B.Systematic review,meta-analysis,and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis[J].Clin Infect Dis,2017,64(12):1670-1677.
[18] CHURCHYARD G J,SWINDELLS S,GUPTA A,et al.Preventing multidrug-resistant tuberculosis:the dawn of a new era[J].Clin Infect Dis,2026,81(6):1135-1140.
[19] World Health Organization.Latent tuberculosis infection:updated and consolidated guidelines for programmatic management[EB/OL].[2026-05-08].https://www.who.int/publications/i/item/9789241550239.
[20] FELKER I,SOLOVYEVA A,CIOBANU A,et al.Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region,2023[J/OL].Eur Commun Dis Bull,2025,30(30)[2026-05-08].https://doi.org/10.2807/1560-7917.ES.2025.30.30.2500210.
[21] BAMRAH S,BROSTROM R,DORINA F,et al.Treatment for LTBI in contacts of MDR-TB patients,federated states of Micronesia,2009-2012[J].Int J Tuberc Lung Dis,2014,18(8):912-918.
[22] MALIK A A,GANDHI N R,LASH T L,et al.Effectiveness of preventive therapy for persons exposed at home to drug-resistant tuberculosis,Karachi,Pakistan[J].Emerg Infect Dis,2021,27(3):805-812.
[23] DUONG T,BRIGDEN J,SIMON SCHAAF H,et al.A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis[J/OL].NEJM Evid,2025,4(1)[2026-05-08].https://doi.org/10.1056/EVIDoa2400190.
[24] AKKERMAN O W,VAN ALTENA R,KLINKENBERG T,et al.Drug concentration in lung tissue in multidrug-resistant tuberculosis[J].Eur Respir J,2013,42(6):1750-1752.
[25] KEMPKER R R,BARTH A B,VASHAKIDZE S,et al.Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis[J].Antimicrob Agents Chemother,2015,59(6):3149-3155.
[26] World Health Organization.WHO operational handbook on tuberculosis:module 1:prevention-tuberculosis preventive treatment(second edition)[EB/OL].[2026-05-08].https://www.who.int/publications/i/item/9789240097773.
[27] NOEL G J,BRADLEY J S,KAUFFMAN R E,et al.Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders[J].Pediatr Infect Dis J,2007,26(10):879-891.
[28] SOLANS B P,MIYAKAWA R,SHIN M,et al.Deriving dosages for levofloxacin tuberculosis preventive treatment for young people exposed to rifampicin-resistant tuberculosis[J].J Infect Dis,2025,232(5):1178-1186.
[29] VAN DER LAAN L E,HESSELING A C,SCHAAF H S,et al.Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children[J].J Antimicrob Chemother,2023,78(10):2481-2488.
[30] WHITE Y N,SOLANS B P,DENTI P,et al.Pharmacokinetics and optimal dosing of levofloxacin in children for drug-resistant tuberculosis:an individual patient data meta-analysis[J].Clin Infect Dis,2024,78(3):756-764.
[31] 中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志,2019,42(10):733-749.
[32] GARCIA-PRATS A J,DRAPER H R,FINLAYSON H,et al.Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis[J].Clin Infect Dis,2018,67(11):1777-1780.
[33] World Health Organization.A5.2 Use of fluoroquinolones for TB preventive treatment in contacts of persons with MDR-/RR-TB:a systematic review[EB/OL].[2026-05-08].https://tbksp.who.int/en/node/2746.
[34] ADLER-SHOHET F C,LOW J,CARSON M,et al.Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis[J].Pediatr Infect Dis J,2014,33(6):664-666.
[35] World Health Organization.Global tuberculosis report 2023[R].Geneva:WHO,2023.
[36] LI M,ZHANG Y Y,WU Z Y,et al.Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai,China:a retrospective population-based genomic epidemiology study[J/OL].Emerg Microbes Infect,2024,13(1)[2026-05-08].https://doi.org/10.1080/22221751.2024.2302837. |
|
|
|
